Results 131 to 140 of about 1,341 (168)

The burden of thyroid eye disease: Evaluating treatment outcomes on quality of life. [PDF]

Eur J Ophthalmol
Lai AC, Yu BE, Malvankar-Mehta M.
europepmc   +1 more source

Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis. [PDF]

Eye (Lond)
Abumohssin AG, Alshareef RA, Aljohani S, Alqutub A, Alqutub A.   +4 more
europepmc   +1 more source

Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions. [PDF]

Front Immunol
Wang L, Chen L.
europepmc   +1 more source

Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison. [PDF]

J Endocr Soc
Kahaly GJ, Xi A, Barretto N, Patel H, Qashqai A, Shokoohi M, Spin P, Holt RJ.   +7 more
europepmc   +1 more source

A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus. [PDF]

Endocrinol Metab (Seoul)
Ko J, Surl D, Lee MJ, Lee JK, Son J, Kim N, Yang J, Yoon JS.   +7 more
europepmc   +1 more source

A Case of Thyroid Dermopathy. [PDF]

Cureus
Day AJ, Sarantopoulos GP.
europepmc   +1 more source

Teprotumumab

Reactions Weekly
Die Wirksamkeit von Teprotumumab bei aktiver Schilddrüsen-bedingter Augenkrankheit wurde in zwei Doppelblindstudien dokumentiert. Ob er längerfristig wirksamer ist als die bisher verwendete Therapie mit Methylprednisolon, ist nicht gesichert.
Etzel Gysling
core   +21 more sources

Teprotumumab: First Approval

Drugs, 2020
Teprotumumab (teprotumumab-trbw; TEPEZZA™ - Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated ophthalmopathy).
Anthony Markham (4891627)
openaire   +3 more sources

Teprotumumab (Tepezza)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Tepezza should not be reimbursed by public drug plans for the treatment of moderate to severe active thyroid eye disease (TED) in adult patients. Evidence from 3 randomized controlled trials (RCTs) in patients with moderate to severe active TED demonstrated that Tepezza improved proptosis and overall ...
CDA-AMC
openaire   +2 more sources